Income Statement (Annual)

ATRS / Antares Pharma, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues
  Revenue From Contract With Customer Excluding Assessed Tax - - - - - - - - -
Cost Of Revenue
  Cost Of Goods And Services Sold - - - - - - - - -
Gross Profit 4,171 8,545 9,661 13,055 11,421 15,265 26,200 23,405 27,049
Operating Expenses
  Research And Development Expense 7,902 8,803 6,699 14,922 15,263 18,638 19,731 21,127 13,147
  Selling General And Administrative Expense - - - 9,585 17,008 31,740 26,931 26,395 30,353
  Operating Expenses 13,865 14,572 14,098 24,507 32,272 50,378 46,662 47,522 43,500
Operating Income Loss -9,694 -6,026 -4,437 -11,452 -20,850 -35,113 -20,462 -24,117 -16,451
Interest Expense -633 -4 -1 - - - - - 1,423
Other Nonoperating Income Expense - -65 49 24 -59 -90 -22 -122 271
Net Income Loss -10,291 -6,091 -4,388 -11,427 -20,507 -35,152 -20,659 -24,339 -16,743
Earnings Per Share Basic And Diluted - - -0 -0 -0 -0 -0 -0 -0
Weighted Average Number Of Share Outstanding Basic And Diluted - - 96,995 110,185 126,897 130,550 146,594 154,992 156,054

Peers - Surgical and Medical Instruments and Apparatus (3841)

Related News Stories

Antares Pharma's testosterone drug gets FDA approval

2018-10-01 reuters
(Reuters) - The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc’s drug to treat low testosterone levels in men, the company said, nearly a year after rejecting the injection.

FDA Action Alert: Merck, Insmed and Antares Pharma

2018-09-24 biospace
The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August. Let’s take a look. (0-6)

Lilly, Teva, Pfizer & Others Await FDA Decisions in September

2018-09-07 zacks
Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 drugs in the full year. (14-3)

Myriad Genetics: When Frustration Overrides Fact

2018-09-06 seekingalpha
Despite deciding earlier in 2018 to hold onto our investment in Myriad Genetics, my investment club opted to divest a portion in July.

Antares Pharma: Proven Business Model Set To Move Much Higher

2018-08-20 seekingalpha
Management strategy of pursuing a combination of proprietary and partnered drugs is derisking future growth while providing enhanced upside with proprietary offerings. (23-2)

CUSIP: 036642106